Carcinoma, Renal Cell: all 1,992 studies

Page 11 of 20. Open to participants first (387), then studies with results posted, then the rest; newest registration first within each.

• A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid MalignanciesActive, not recruitingNCT05199272Phase 1/2
• Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell CarcinomaCompletedNCT05188118Early Phase 1
• Clinical-pathological Characterization and Outcomes of Renal Cell Carcinoma in Latin AmericanCompletedNCT05184504
• Tempus Priority Study: A Pan-tumor Observational StudyActive, not recruitingNCT05179824
• Avelumab, Palbociclib and Axitinib in Advanced RCCWithdrawnNCT05176288Phase 2
• Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617Status unknownNCT05170555Not applicable
• Complications Associated With Partial Nephrectomy for Renal CancerCompletedNCT05168761
• A Study of Preferences of Participants and Oncologists for the Characteristics of the Treatment for Renal Cell Carcinoma (RCC) In Spain And PortugalCompletedNCT05168436
• Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell CancerActive, not recruitingNCT05148546Phase 2
• Patient Reported Outcomes by Patients With Metastatic Renal Cell CarcinomaStatus unknownNCT05135832Not applicable
• A Study of NDI 1150-101 in Patients With Solid TumorsActive, not recruitingNCT05128487Phase 1/2
• Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell CarcinomaStatus unknownNCT05124431Phase 2
• CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney CancerActive, not recruitingNCT05122546Phase 1
• A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)TerminatedNCT05121948Phase 1
• A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell CarcinomaTerminatedNCT05119335Phase 1/2
• A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell CarcinomaTerminatedNCT05119010Not applicable
• Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid TumoursCompletedNCT05114668Phase 1
• Immunophenotyping in Metastatic Kidney Cancer Patients Receiving Ablative TherapyCompletedNCT05112627
• Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer CellsStatus unknownNCT05108077Phase 1/2
• A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon CarcinomaWithdrawnNCT05104905Phase 1/2
• Combined Aerobic and Resistance Exercise Training in Metastatic Renal Cell CarcinomaTerminatedNCT05103722Not applicable
• Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IOActive, not recruitingNCT05078047Phase 3
• Circulating Tumor Cell Reducing No-touch NephrectomyCompletedNCT05070637Not applicable
• Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)Active, not recruitingNCT05056077Not applicable
• Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCActive, not recruitingNCT05043090Phase 3
• Predictive Imaging Features in Renal Cell CarcinomaCompletedNCT05042089
• A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)Active, not recruitingNCT05030506Phase 1
• Ask Questions (ASQ):Implementation of a Communication InterventionCompletedNCT05025748Not applicable
• Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic MalignanciesActive, not recruitingNCT05013099Phase 2
• Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell CancerActive, not recruitingNCT05012371Phase 2
• Yorkshire Kidney Screening TrialStatus unknownNCT05005195Not applicable
• Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell CarcinomaStatus unknownNCT04995016Phase 2
• Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell CarcinomaCompletedNCT04987203Phase 3
• Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to DrugsWithdrawnNCT04985357
• Occupational Therapy Fatigue Management-Based Intervention for Metastatic Renal Cell CarcinomaWithdrawnNCT04961320Not applicable
• NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNtsCompletedNCT04960059
• Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing CombinationCompletedNCT04957160
• Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing SurgerySuspendedNCT04955808
• Prospective Validation of the Prognostic Value of Long Non-coding MFI2-AS1 RNA in Localized Clear Cell Kidney CancersStatus unknownNCT04946266
• Quantifying Systemic Immunosuppression to Personalize Cancer TherapyWithdrawnNCT04941365Not applicable
• LPN in Patients With High-complex Renal TumorsCompletedNCT04933604
• Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell CarcinomaActive, not recruitingNCT04919122
• REduced Frequency ImmuNE Checkpoint Inhibition in CancersStatus unknownNCT04913025Phase 2
• Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell CancerTerminatedNCT04904302Phase 2
• DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other MalignanciesTerminatedNCT04895748Phase 1
• Prospective Translational Study Investigating Predictors of Outcome in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab (I-Rene Trial)Status unknownNCT04891055
• A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various CancerWithdrawnNCT04889495
• Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney CancerCompletedNCT04883827
• Significance of Immunohistochemical Expression of Survivin in Renal Cell CarcinomaCompletedNCT04873180
• A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)CompletedNCT04846920Phase 1
• A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)CompletedNCT04834778Phase 1
• Research on the Effectiveness and Safety of Remote Control of Domestic Surgical Robot System for Urinary SurgeryCompletedNCT04804163Early Phase 1
• Measuring Treatment Response in Metastatic Renal Cell Cancer Using FPIA PET/CTCompletedNCT04802824
• The Evaluation of Functional Parenchymal Volume and Split Renal Function Before and After Partial NephrectomyStatus unknownNCT04798963Not applicable
• App-Based Mindfulness Intervention for the Improvement of Quality of Life in Patients With Metastatic Renal Cell CancerActive, not recruitingNCT04788095Not applicable
• Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and DostarlimabTerminatedNCT04779151Phase 2
• A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid TumorsCompletedNCT04773951Phase 1
• Fecal Microbiota Transplantation to Improve Efficacy of Immune Checkpoint Inhibitors in Renal Cell CarcinomaCompletedNCT04758507Phase 1/2
• 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain MetastasesCompletedNCT04752267Early Phase 1
• Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.CompletedNCT04749602Phase 2
• A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)Active, not recruitingNCT04736706Phase 3
• the Efficacy and Safety of LDP in Patients With Urinary and Male Genital TumorsCompletedNCT04718584Phase 2
• DNX-2440 for Resectable Colorectal Liver MetastasisSuspendedNCT04714983Phase 1
• Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell CarcinomaStatus unknownNCT04714697Phase 2
• A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian TumorsActive, not recruitingNCT04707248Phase 1
• Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell CarcinomaStatus unknownNCT04698213Phase 2
• Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell CarcinomaActive, not recruitingNCT04696731Phase 1
• A Study of PY314 in Subjects With Advanced Solid TumorsTerminatedNCT04691375Phase 1
• iConquerFear Program for the Treatment of Fear of Cancer Recurrence in Patients With Localized Renal Cell CarcinomaWithdrawnNCT04688333
• Multimodal Machine Learning Characterization of Solid TumorsCompletedNCT04687969
• Tissue Collection to ID TCRs From Renal Clear Cell Carcinoma Patients Responding to Immune Checkpoint InhibitorsWithdrawnNCT04680416
• Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced CancerCompletedNCT04670445Not applicable
• Evaluating the Bacterial and Fungal Microbiome in Patients With Calcium Oxalate Urolithiasis and Renal Cell CarcinomaSuspendedNCT04669860
• Contrast Ultrasound Dispersion Imaging (CUDI) as a Diagnostic Modality in the Diagnosis of Renal Cell CarcinomaStatus unknownNCT04669613Not applicable
• VETC, Prognostic and Predictive Value in Renal Cell Carcinoma and Adrenal CarcinomaStatus unknownNCT04666220
• Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial MalignanciesWithdrawnNCT04648826Phase 1/2
• Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell CarcinomaStatus unknownNCT04644432Phase 2
• Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in EnglandCompletedNCT04637204
• Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)CompletedNCT04626518Phase 1/2
• Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)CompletedNCT04626479Phase 1/2
• Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in CancerActive, not recruitingNCT04620603Phase 1
• Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France.WithdrawnNCT04609800
• Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell CarcinomaStatus unknownNCT04609293
• A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid TumorsActive, not recruitingNCT04606472Phase 1
• Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell CancerWithdrawnNCT04603365Phase 2
• Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid TumorsStatus unknownNCT04602702
• Advantage of a Fast-recovery Protocol for Minimally Invasive Kidney SurgeryCompletedNCT04601129
• A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)Active, not recruitingNCT04586231Phase 3
• MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK TrialWithdrawnNCT04580836Phase 2
• Efficacy and Safety of Clinical Telesurgery Using Chinese Independently Developed Surgical Robot SystemCompletedNCT04570176Not applicable
• Axitinib Therapy Management StudyWithdrawnNCT04555603
• A Phase 1 Study of GNR-051 in Subjects With Advanced MalignanciesCompletedNCT04544748Phase 1
• A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has SpreadCompletedNCT04540705Phase 1
• Fear of Cancer Recurrence in Genitourinary CancerCompletedNCT04535921
• Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell CarcinomaCompletedNCT04535687Phase 2
• Robotic-assisted vs. Open Partial NephrectomyStatus unknownNCT04534998Phase 2
• A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal CancerActive, not recruitingNCT04523272Phase 3
• A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell CarcinomaActive, not recruitingNCT04522323Phase 1
• Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid MalignanciesCompletedNCT04518046Phase 1
• Spanish Real-World Evidence CabozantinibCompletedNCT04510688

← Carcinoma, Renal Cell overview